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in dermatology
Christopher Iriarte1
Olabola Awosika2
Monica Rengifo-Pardo1,2
Alison Ehrlich1,2
1George Washington University 
School of Medicine and Health 
Sciences, Washington, DC, USA; 
2Department of Dermatology, The 
George Washington Medical Faculty 
Associates, Washington, DC, USA 
Abstract: Microneedling (MN) is a novel therapeutic modality in dermatology. Through 
physical trauma from needle penetration, MN induces a wound healing cascade with minimal 
damage to the epidermis. This allows for enhancement in the absorption of mainstay topical 
therapies across the thick stratum corneum. MN has become increasingly utilized over the last 
several years as it is a relatively simple procedure that is cost-effective, well tolerated, and offers 
both cosmetic and therapeutic benefits. The ability to treat localized areas of disease has led to 
numerous studies gauging its potential in focal diseases of inflammation, dyschromia, and pho-
todamage. This review discusses the principles and evidence behind the expanding applications 
of MN. It has shown promising results as an adjuvant therapy for enhanced drug delivery in the 
treatment of atrophic scars, alopecia, actinic keratoses, and disorders of pigmentation such as 
melasma. The efficacy in treatment of vitiligo remains limited. Overall, the procedure has few 
adverse sequelae compared to other therapies, is highly efficacious, and is a viable resurfacing 
option for skin of color. Future research is needed to determine the frequency, interval, and 
specific device settings that foster optimal results. Additionally, large controlled trials are needed 
to shed light on the utility of MN as an evidence-based regimen for the treatment of various 
dermatologic conditions. 
Keywords: microneedling, scars, acne, alopecia, hyperpigmentation, actinic keratosis 
Introduction
Microneedling (MN), also known as collagen induction therapy, is a process involving 
repetitive puncturing of the skin with sterilized microneedles. Its original conception 
can be traced back to 1995, when Orentreich and Orentreich developed the concept of 
“subcision”, or using hypodermic needles to induce wound healing in depressed cutaneous 
scars.1 In 2006, Dr. Desmond Fernandes developed the first MN product which became the 
modern-day Dermaroller® (Dermaroller Deutschland GmbH, Wolfenbuettel, Germany).2
MN offers a relatively low cost and minimally invasive tool for the treatment of 
multiple cosmetic and dermatologic conditions.3 The basis of MN relies on physical 
trauma. It has been proposed that the trauma generated by needle penetration in the 
skin induces regeneration of the dermis.4 The needles penetrate the stratum corneum 
and create small holes known as micro-conduits with minimal damage to the epidermis. 
This sequentially leads to the generation of growth factors which stimulate the produc-
tion of collagen and elastin in the papillary layer of the dermis.3 The natural wound 
healing cascade is induced as platelets and neutrophils are recruited to release growth 
factors such as TGF-alpha, TGF-beta, and platelet-derived growth factor (PDGF).2 
This ultimately results in the deposition of collagen by fibroblasts. 
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A variety of MN products have been developed to treat 
scarring and wrinkles, enable skin rejuvenation, and improve 
skin appearance.5 Clinical trials over the last several years 
have shed light on the applications of MN beyond cosmetic 
indications, including actinic keratoses (AK), disorders of 
pigmentation, hyperhidrosis, and striae.6 Additionally, the 
role of MN in the treatment of hair pathology has become a 
recent field of focus as it is thought to stimulate stem cells in 
the dermal papilla, increase blood flow to hair follicles, and 
recruit growth factors and signaling pathways which induce 
hair restoration.7 MN is also postulated to induce normal 
wound healing, specifically by breaking collagen strands in 
the superficial dermis and inducing collagen synthesis imme-
diately under the epidermis.8 This mechanism is the guiding 
principle behind the application of MN in the treatment of 
scars of various etiologies.
This review of the literature is focused on exploring the 
expanding indications of MN. In addition, this review will 
highlight the efficacy and adverse effect prolife of MN in 
comparison with more common treatment modalities used 
for various indications in dermatology. 
Methods
The studies selected for this review were gathered by search-
ing the PubMed, MEDLINE, Cochrane databases, and elec-
tronic journals of dermatology. The search terms used for 
this review included “microneedling”, “collagen induction”, 
“reviews”, and “trials”. Only articles published in English 
were considered for inclusion in this review. Articles were 
obtained in all circumstances and references were checked for 
additional information when considered applicable. Available 
studies involving human subjects were included in the review. 
Additionally, only studies regarding manual MN techniques 
were considered for inclusion. Priority was given to con-
trolled clinical trials, both prospective and retrospective, with 
a minimum of ten patients as the sample size. Uncontrolled 
clinical trials were included so long as a statement was made 
regarding the study’s experimental design and limitations. 
Smaller case series with less than ten patients were included 
if they were the only available data for specific indications 
such as alopecia areata (AA) or verruca plantaris. 
Types of MN
Currently, there are many mechanical MN devices registered 
with the US Food and Drug Administration (FDA), with the 
majority being a variation of either the Dermaroller or the 
Dermapen® (Dermapen, Salt Lake City, UT, USA). The Der-
maroller is a hand-held device with a cylindrical roller of 24 
circular arrays.6,9 Each array is equipped with eight medical 
grade solid steel microneedles, totaling to 192 needles on one 
Dermaroller device.6,9 The device is used in a multi-directional 
fashion (vertically, horizontally, and diagonally) directly over 
the skin. Medical models include the CIT 8™ and MF 8™, 
which consist of needle heights of 500 µm and 1,500 µm, 
respectively.6 Various models have also been developed for 
use in the home, including the Beauty Mouse®  (Dermaroller 
Deutschland GmbH) which consists of 480 needles to use on 
larger skin surfaces.5 The Dermapen is a spring-loaded MN 
device which acts as an electrically powered pen, delivering 
stamp-like motions across the skin.10 Several commercial 
variations of this device exist based on the same principles.
Other devices use additional technology to build upon 
the applications of mechanical MN. Indications for these 
newer modalities include superficial scars, hyperhidrosis, and 
wrinkles.6 These MN modalities include fractional radiofre-
quency microneedling (FRFM), DermaFrac™ (Genesis Bio-
systems, Lewisville, TX, USA), light emitting diode (LED) 
MN devices, and MN delivery systems.6 FRFM is differenti-
ated from manual MN due to the method of each insulated 
needle releasing a radiofrequency current from the needle 
tip producing changes in dermal structural components.6,11 
In DermaFrac treatment, MN is combined with microderm-
abrasion, LED light, and simultaneous serum infusion into 
the dermis.6 LED MN rollers combine solely LED light and 
MN. MN delivery systems are a method of transdermal drug 
administration in which solid microneedles pierce the skin 
followed by topical drug application. Alternatively, drugs 
can be delivered directly into the dermis through hollow 
needles.12 Of note, in 2011, Fluzone® Intradermal influenza 
virus vaccine (Sanofi Pasteur, Swiftwater, PA, USA) became 
the first and only microneedle-based product approved by the 
FDA for this process.13,14 It is recommended that the use of 
MN to enhance absorption of topical agents be performed 
with caution as non-sterilized drugs may contain particles 
that penetrate the skin to varying degrees and contribute to 
further complications, such as infection due to the permeation 
of pathogenic microbes.12 
Applications of MN
The sections that follow will provide an overview of the 
clinical trials in dermatology that have been performed 
with manual MN, as well as several case series. Specific 
information regarding study design, treatment intervals, 
MN devices used, and comparative efficacy can be found in 
the accompanying tables. These tables summarize the major 
studies covered in this review for each respective indication 
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that follows. Each section concludes with our summary of 
the current state of the literature and future areas for research 
specific to each indication. 
Scars 
Several studies show efficacy of MN for scar treatment 
(Table 1). In a pilot study, El-Domyati et al quantified the 
histological changes induced by MN in ten patients with 
atrophic facial scars from acne.15 Skin biopsies were obtained 
at baseline and post-treatment with Dermaroller. There 
was a statistically significant increase in the production of 
collagen types I, III, and VII and a decrease in total elastin 
by the end of treatment (p < 0.05). All patients reported 
mild pain and edema at the treatment site which resolved 
within 24 hours. Otherwise, no adverse effects were noted. 
Patients collectively reported a 51%–60% improvement in 
scar appearance, 40%–50% improvement in skin texture, 
and 80%–85% overall satisfaction (p = 0.001) following six 
treatment sessions over the course of 3 months.15 
In a cohort study, Majid relied on clinical outcomes rather 
than histologic changes to assess improvement of atrophic 
facial scars in response to MN therapy.16 Thirty-seven patients 
were offered Dermaroller treatments and followed over the 
course of 2 months. Over 80% of the patients assessed their 
response to treatment as “excellent” on a 10-point scale. 
Of the patients who completed the study, 94.4% graded the 
reduction in the severity of their scars by at least one objec-
tive grade. No adverse effects were noted.16 
A clinical trial by Garg and Baveja assessed the efficacy 
of combination therapy using subcision, MN, and 15% tri-
chloroacetic acid peel in the management of 50 patients with 
atrophic acne vulgaris scars.17 The patients were treated for a 
total of six sessions with scar grading done at baseline and 1 
month after treatment. Complete remission was demonstrated 
in all patients with Grade 2 scars and 22.7% of patients with 
Grade 3 scars. Additionally, of the 16 patients with Grade 4 
scars at baseline, ten patients improved to Grade 2 and the 
remaining six improved to Grade 3. Overall, 100% of patients 
had objective improvement in scars by at least 1 grade. 
Adverse events other than transient erythema and edema 
included acne eruptions, post-inflammatory hyperpigmenta-
tion (PIH) resolving after 5 months of topical treatment (with 
combination of tretinoin, hydroquinone, and mometasone), 
and cervical lymphadenopathy lasting 3 weeks.17
Several studies have also compared the efficacy of laser 
and MN treatments. Cachafeiro et al compared 1,340 nm non-
ablative fractional erbium laser and Dr. Roller™ (Vydence 
Medical, São Carlos, São Paulo, Brazil) for the treatment of 
46 patients with facial atrophic acne scars.18 These patients 
were randomized to one of the two groups and received three 
treatment sessions monthly regardless of assignment. Both 
groups demonstrated improvement at 2 and 6 months post-
treatment, with no statistically significant difference between 
them (p = 0.264). While efficacy was similar, the adverse 
event profile varied. The MN group experienced erythema for 
an average of 1 day compared to the laser group, for which 
the erythema lasted an average of 3 days. Additionally, 13.6% 
of the patients in the laser group experienced PIH while none 
of the patients in the MN group did.18 
Another emerging field of study in MN is its applicability 
in the treatment of scars in various ethnic groups. One clinical 
trial by Dogra et al evaluated the utility of MN for treating 
atrophic acne scars in Asian populations.19 On an objec-
tive scale of 18 points, patients’ assessments of their scars 
decreased from 11.73 to 6.5 following five MN  treatments, 
indicating significant improvement. In a study with patients 
of darker pigmented skin, the use of MN combined with gly-
colic acid peels for the treatment of acne scars was assessed 
in 30 Indian patients with atrophic box type and rolling scars 
with PIH.20 Patients were assigned to receive treatment with 
MN only or with MN and 35% glycolic acid peels. There 
was significant improvement in skin texture, scarring, and 
a reduction in PIH in the group treated with the combined 
approach when compared to MN alone (p = 0.001).20 
MN has also been used to enhance treatment of hyper-
trophic surgical scars by increasing drug delivery of topical 
agents to the dermis.21 Aust et al demonstrated MN to be 
an effective alternative for burn patients with hypertrophic 
scars.22 In this study, 16 patients with post-burn scarring 
were treated with MN after 4 weeks of preparation with 
topical vitamin A and C to maximize collagen production. 
Each patient reported satisfaction with scar appearance on 
an objective visual analog scale (VAS) from 1 to 10, with 
10 indicating the most satisfaction. Prior to treatment, the 
average VAS score was 4.5. This score increased to 8.5 fol-
lowing one to four sessions of MN treatment with continued 
application of topical vitamin A and C twice daily. Histologic 
analysis of 3 mm punch biopsies at 1 year demonstrated an 
increase in collagen and elastin deposition both quantita-
tively and qualitatively using van Gieson and hematoxylin 
and eosin stains. 
Studies with various-sized MN devices that evaluate the 
frequency and interval between treatments for optimal effects, 
would be an appropriate next step in further elaborating on the 
efficacy of MN. Many of the aforementioned studies demon-
strated that MN had comparable efficacy to laser treatments 
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for atrophic facial scars. However, MN is generally better 
tolerated with fewer long-term adverse sequelae.23 Scar type 
appears to be a factor affecting clinical response to MN, as 
icepick scars and deep-seated atrophic scars responded less 
ideally to treatment.15
Alopecia
MN has been proposed as a mechanism for adjuvant hair 
regrowth in alopecia. The efficacy of MN in both androge-
netic alopecia (AGA) and AA has been highlighted over the 
last 5 years (Table 2). 
AGA
Dhurat et al found that combination treatment of MN with 
minoxidil was statistically superior to minoxidil alone in the 
treatment of 100 male patients with AGA.24 Over 12 weeks, 
Dermaroller treatment combined with 5% minoxidil lotion 
was administered to half of the participants, with 80% 
showing moderately or greatly increased hair regrowth per 
the investigators. Of the same subset, 82% of the patients 
reported subjective improvement greater than 50% in their 
hair growth. In the arm receiving 5% minoxidil alone, only 
4.5% of patients reported greater than 50% improvement. By 
the end of the study, mean change in hair count was signifi-
cantly greater for the MN group (91.4 vs. 22.2, p = 0.039). 
Table 2 Alopecia treated with microneedling therapy
Reference Adjunctive  
therapy +/- 
MN therapy
Needle 
depth
Type of 
alopecia
Study design No of 
patients  
(N) 
No of 
sessions 
(interval) 
Results
Dhurat et al, 
201324
5% topical 
minoxidil +/- 
Dermaroller 
1.5 mm AGA Prospective, 
evaluator-blinded 
RCT
100 12 (1 week) Mean hair counts were 
significantly greater in MN + 
minoxidil group compared 
to minoxidil alone group 
(91.4 vs. 22.2, p = 0.039). 82% 
in combination group reported 
greater than 50% improvement 
vs. 4.5% in minoxidil group.
Dhurat and 
Mathapati, 
201525
5% topical 
minoxidil and 
oral finasteride 
+/- Dermaroller 
1.5 mm AGA Case series 4 4 (1 week) then 
11 (2 weeks) 
100% showed +2 or +3 responses 
on a 7-point standardized scale 
for hair growth. Findings were 
sustained at final follow-up. 75% 
had subjective improvement in 
hair growth > 75%.
Chandrashekar 
et al, 201426 
0.1% topical TAC 
+/- Dermaroller 
1.5 mm AA Case series 2 3 (3 weeks) 100% graded hair regrowth as 
“excellent” at 3-week follow-up 
with no recurrence of AA at 
12 weeks.
Notes: Dermaroller®; Dermaroller Deutschland GmbH, Wolfenbuettel, Germany. 
Abbreviations: MN, microneedling; N, sample size; AGA, androgenetic alopecia; RCT, randomized controlled trial; TAC, triamcinolone; AA, alopecia areata.
Additionally, the initiation of new hair growth was first 
noticeable at 6 weeks in the MN group compared to 10 weeks 
in the minoxidil alone group. No adverse effects were noted 
by any of the participants.24 
Dhurat and Mathapati then published a follow-up case 
series of four men with AGA unresponsive to conventional 
treatments. Combination therapy was administered to par-
ticipants with their prior treatment regimen (either topical 
minoxidil or oral finasteride) and Dermaroller over a course 
of 6 months.25 All four patients had moderately or greatly 
increased hair regrowth and reported subjective increases in 
hair thickness after 1 month of treatment.25 
AA
MN has been proposed as a viable alternative to conventional 
treatment for AA as well. The mainstay of therapy for AA 
is currently intralesional corticosteroids, such as kenalog 
(ILK). However, the collagen induction offered by MN is 
thought to counter steroid-induced atrophy as well as cause 
less pain than injection.26
Chandrashekar et al analyzed outcomes from treating 
resistant AA with MN and topical corticosteroids.26 Two 
adult patients with AA recalcitrant to ILK, topical steroids, 
and minoxidil 5% lotion received topical triamcinolone 
applied before and after Dermaroller. Both patients graded 
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hair regrowth as “excellent” and had no recurrence at 
3-month follow-up. The ability to assess for common 
adverse effects of steroid treatment such as atrophy, scar-
ring, and increased susceptibility to infection were limited 
in this study. 
While these clinical studies show promising data for the 
efficacy of MN in the treatment of alopecia, these results 
are limited by relatively small sample sizes. Additionally, it 
is unclear if similar results are reproducible in women with 
hair disorders. Further investigations of combination therapy 
with minoxidil and finasteride, including MN frequency, 
needle size, and duration of treatment are needed to see if 
these results are reproducible in both genders and sustained 
over longer periods of time. 
Pigmentary disorders 
Several studies have proposed MN as an alternative to con-
ventional treatment in disorders of pigmentation affecting 
darker skin types, including melasma, vitiligo, and periorbital 
hyperpigmentation (Table 3).
Melasma
The enhanced transdermal drug absorption seen with MN has 
achieved better results than skin lightening agents alone in 
the treatment of melasma.27–29 Budamakuntla et al observed 
enhanced results of MN followed by topical tranexamic acid 
in comparison to tranexamic acid microinjections in treat-
ing moderate to severe melasma in 60 patients.30 After three 
treatment sessions (at 0, 4, and 8 weeks), the patients were 
followed for 3 months. There was 35.72% improvement in the 
mean Melasma Area and Severity Index (MASI) score in the 
microinjection group (p < 0.01) compared to 44.41% in the 
MN group (p < 0.001). Notably, only 26% of patients in the 
microinjection group achieved 50% improvement compared 
to 41% in the MN group. Neither group experienced major 
side effects, but some reported mild discomfort, burning 
sensation, and erythema.30
In a pilot study, the use of depigmentation serum con-
taining 4-butylresorcinol and sophora-alpha (prenylated 
flavonoids from the roots of Sophora flavescens) alone was 
compared to the combination treatment of depigmentation 
serum and MN (MN + serum) in 20 female patients (Fitzpat-
rick Skin Type III–IV) with melasma.27 In the MN + serum 
group, baseline mean MASI score decreased by 9.9 points 
(p < 0.001) compared to a 7.1 point decrease (p < 0.05) in 
the serum only group 2 months post-treatment. Results were 
confirmed by the significant increase in brightness of patients 
receiving combination treatment in comparison to the group 
receiving serum alone (17.4% vs. 11.2%; p < 0.05).27 
MN combination therapy also has favorable results in 
melasma when combined with daily sunscreen use. In a 
retrospective analysis of 22 cases of recalcitrant melasma 
(unresponsive to topical bleaches and sunscreen), MN was 
administered followed by night time application of a depig-
mentation formula (0.05% tretinoin + 4% hydroquinone + 
1% fluocinonide acetonide) and daily tinted sunscreen (SPF 
60) 24 hours after initial skin needling.31 The procedure was 
repeated 30 days after the first treatment. All 22 patients 
reported satisfaction with results at 2 month follow-up. Pho-
tographic analysis at 24-month follow-up in eleven patients 
demonstrated continued maintenance of skin lightening 
observed at the 2-month visit.31
Vitiligo
The efficacy of MN in combination treatment for vitiligo 
remains unclear. Stanimirovic et al investigated repigmenta-
tion of patients with resistant bilateral symmetrical vitiligo 
by comparing treatment with narrowband ultraviolet B and 
topical 0.005% latanoprost solution with and without Derma-
roller.32 Seventeen patients in each group had repigmentation 
(37.8% of treated lesions) and only 8.8% of repigmenting 
lesions had greater than 50% repigmentation. However, there 
was no statistically significant difference in repigmentation 
between groups.32 
Periorbital melanosis
MN therapy has been successful in the treatment of peri-
orbital hyperpigmentation. One male patient demonstrated 
75%–90% improvement with DermaFrac treatment (com-
bination of MN and active ingredients, including kojic acid 
or anti-aging serum containing myristoyl pentapeptide 17 
[SymPeptide], acetyl octapeptide-3 [SNAP 8], palmitoyl 
pentapeptide-4 [Matrixyl], acetyl hexapeptide-8 [Argirilene] 
and tripeptide [Syn-ake]) after 12 sessions.33 The patient also 
reported 7 out of 10 improvement on the Patient’s Global 
Assessment scale in his pigmentation. 
Kontochristopoulos et al also explored the use of MN 
in periorbital hyperpigmentation by treating 13 female 
patients with MN followed by 10% trichloroacetic acid 
peels.34 Almost all patients (92.3%) demonstrated signifi-
cant improvement (“fair or better”) according to patient 
global assessments. Transient side effects including 
mild discomfort, edema, and erythema were commonly 
observed.34 
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MN therapy is promising in melasma and periorbital 
melanosis. Notably, MN poses a viable alternative to resur-
facing procedures for darker skinned patients, given the lack 
of dyspigmentation as an adverse event. However, there are 
limited data to support its potential in improving vitiligo. 
Hence, there is a need for randomized controlled studies with 
larger populations to further explore the potential of MN as a 
treatment for pigmentation disorders in skin of color.
Verruca
The benefits of MN as a method of drug delivery in verruca 
was seen by Konicke and Olasz achieving complete cure rate 
in three patients (Table 4). MN was used in combination with 
0.2–0.5 mL of topical bleomycin at 1 unit per mL over an 
average of 4 treatments.35 Notably, there was no tissue necro-
sis as seen with intralesional bleomycin and patients reported 
minimal pain. Comparatively, cure rates with intralesional 
bleomycin range from 0% to 95%, with variability attributed 
to poor infiltration of the lesion.36 MN may be a viable option 
for guaranteeing complete cure rates in plantar warts through 
enhancing the delivery of bleomycin in lesions. 
Clinical trials with large sample sizes are needed to 
elucidate the actual role of MN in the treatment of verruca. 
The above study focused on the treatment of isolated verruca 
plantaris; thus, large clinical trials analyzing the efficacy of 
MN in the treatment of common warts would be an area of 
further research. 
Actinic keratoses
Patients with AK have shown mixed results from MN as 
adjunctive therapy to currently accepted treatments (Table 5). 
In a split-face study, Torezan et al evaluated the use of MN 
after application of methyl aminolevulinate photodynamic 
therapy (MAL-PDT) compared to the use of MAL-PDT 
without MN in ten patients with AK.37 MAL-PDT combined 
with Dermaroller (MN-MAL-PDT) had greater improvement 
than MAL-PDT alone for all measured parameters, including 
photoaging and facial erythema (p = 0.01 for global score). 
Table 4 Verruca plantaris treated with microneedling therapy
Reference Adjunctive  
therapy +/- MN 
therapy 
Needle depth Study design No of patients 
(N) 
No of sessions 
(interval) 
Results
Konicke and 
Olasz, 201635
Bleo +/-
MN pen
2.0 mm Case series 3 3–5 
(2–4 weeks) 
Complete cure rate was achieved in 
100% of patients after an average of 
4 treatments every 2–4 weeks.
Abbreviations: MN, microneedling; N, sample size; Bleo, 0.2–0.5 mL of topical bleomycin; MN pen, microneedling pen-type device.
Table 5 Actinic keratoses treated with microneedling therapy
Reference Adjunctive  
therapy +/- 
MN therapy 
Needle 
depth
Study design No of  
patients (N) 
No of sessions 
(interval) 
Results
Torezan et al, 
201337 
MAL-PDT +/- 
Dermaroller 
1.5 mm Split-face, 
prospective RCT
10 1 Average AK clearance was 88.3% overall, 
but there was no statistically significant 
difference in clearance rates between groups. 
MN group had improvement in wrinkles 
and erythema. MN group had greater 
improvement for all measured parameters, 
including global score (p = 0.01).
Spencer and 
Freeman, 
201638
ALA-PDT +/-
Eclipse 
Micropen Elite
0.5 mm Split-face, 
blinded, 
prospective RCT
19 1 Mean reduction in AK was 89.3% in the MN 
group vs. 69.5% in the PDT alone group 
(p < 0.05). 87% in MN group had noticeable 
cosmetic improvement compared to 11% in 
PDT alone group. 
Bencini et al, 
201239 
MAL-PDT +/- 
Dermaroller 
MC905
0.5 mm Uncontrolled, 
prospective 
clinical trial 
12 3 (2 weeks) 100% demonstrated a complete response 
(grade 0, “excellent”) after 3 treatment 
sessions. 83% remained without AK at 
9-month follow-up.
Notes: Dermaroller®; Dermaroller Deutschland GmbH, Wolfenbuettel, Germany. Eclipse Micropen Elite™; Eclipse Aesthetics, Dallas, TX, USA. Dermaroller MC905™; 
Alpha Strumenti, Milan, Italy.
Abbreviations: MN, microneedling; N, sample size; MAL-PDT, methyl aminolevulinate photodynamic therapy; RCT, randomized controlled trial; AK, actinic keratoses; 
ALA-PDT, delta aminolevulinic acid photodynamic therapy.
Clinical, Cosmetic and Investigational Dermatology 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
297
Microneedling: review of the literature
Average AK clearance was 88.3%, with no statistically sig-
nificant difference between the treatment arms (90.5% for 
MN-MAL-PDT side vs. 86% for MAL-PDT side). Pain level, 
based on VAS score, was greater on the MN-MAL-PDT side 
(6 vs. 4, p = 0.004). No prolonged side effects were observed. 
One patient in the MN group did develop a secondary bacte-
rial infection which required treatment with oral antibiotics.37
Spencer and Freeman demonstrated MN can enhance 
topical delta aminolevulinic acid PDT (ALA-PDT) in the 
treatment of AK.38 In their split-face study, 20 patients with 
at least four non-hyperkeratotic AK on each side of the face 
were randomly assigned to either MN therapy with Eclipse 
Micropen Elite™ followed by ALA-PDT or ALA-PDT 
alone. Researchers found a statistically significant differ-
ence (p < 0.05) between treatment groups, as average AK 
clearance was 89.3% in the MN-assisted side and 69.5% in 
the PDT only side. Furthermore, a blinded assessment found 
15 patients achieved significant cosmetic improvement after 
4 months, with 13 of the 15 patients having been in the MN 
treatment group. The procedure was safe and well tolerated 
with no significant side effects reported.38 
The use of MN to treat AK was also evaluated in 12 organ 
transplant recipients with 59 AK unresponsive to classic PDT 
therapy.39 They received three sessions of cyclic PDT with 
use of Dermaroller MC905™ prior to topical application of 
16% MAL. All lesions demonstrated a grade 0 (excellent) 
response after three sessions and were free of any new AK for 
at least 4 months. At 9 month follow-up, two of the patients 
had relapsed while the others remained clear. No adverse 
events were reported. The lack of a PDT alone comparison 
arm impaired the ability to assess the advantage offered solely 
by MN in the treatment of recurrent AK.39
Overall, MN shows promising results as an adjuvant 
therapy for the treatment of refractory AK. Large controlled 
clinical trials are needed to determine the utility of using MN 
for AK, especially on areas of the body other than the face. 
Conclusion 
Since the development of the first Dermaroller 20 years 
ago, a variety of new MN devices have been introduced. 
Accordingly, the applications of MN in dermatology have 
expanded to numerous indications over the past several years. 
This review highlights evidence of the potential for MN in 
the treatment of several dermatologic conditions, including 
disorders of pigmentation, premalignant lesions such as AK, 
scarring secondary to acne and surgical procedures, and hair 
pathologies. Advantages include, but are not limited to, the 
good tolerability of treatment among patients, increased 
transdermal delivery of drugs, and practicality of use in skin 
of color. Transient erythema is the most common adverse 
event.3 Granulomatous reaction in response to unauthorized 
use of topical products not approved for intradermal injection 
has been reported in three patients receiving MN therapy at 
medical spas.40 Otherwise, adverse events are rare and never 
result in systemic toxicity.3 Additionally, histologic analysis 
of skin following MN treatment has demonstrated an intact 
epidermis with no changes in melanocyte number, thereby 
having minimal risks of dyspigmentation relative to currently 
accepted treatments.41 Overall, MN offers a simple yet cost-
effective therapeutic modality with minimal adverse events 
and a promising safety profile. 
It is important to keep in mind that most comparative 
studies on MN have been case reports, case series, or small 
randomized controlled trials. Future large controlled clinical 
trials exploring the utility of MN are imperative to provide 
validation as more than a cosmeceutical therapy and as an 
evidence-based treatment option for patients with a variety of 
dermatologic disorders. This would help offset any potential 
publication bias as it is likely that small negative MN studies 
may not get published. Furthermore, the necessary number of 
treatment sessions and ideal MN settings including needling 
length and depth should be explored. Lastly, research eluci-
dating the details of the mechanism of action of MN specifi-
cally in the treatment of alopecia and pigmentary disorders 
would be beneficial, as the micro-conduits created by MN 
are fast-healing and increased delivery in the dermis may 
not be the sole contributor to observed effects in these areas. 
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